Journal of the American Academy of Child & Adolescent Psychiatry
New researchAnhedonia Predicts Poorer Recovery Among Youth With Selective Serotonin Reuptake Inhibitor Treatment–Resistant Depression
Section snippets
Study Overview
A brief description of method, study design, and sample as relevant to the current study is presented below, and further details are provided elsewhere.3 The study was approved by internal review boards local to the six research sites. All participants gave informed consent/assent (as appropriate), and parents gave informed consent.
Study Participants
Participants were 334 adolescents aged 12 through 18 years who were in active treatment with an SSRI for major depressive disorder (by DSM-IV criteria), and
Baseline Dimension Scores and Remission Through Continuation Treatment
Through 24 weeks, 130 youth (38.9%) achieved remission. For univariate models, higher levels of Reported Depressed Mood, Anhedonia, and Somatic Symptoms, but not Morbid Thoughts or Observed Depression, predicted a longer time until remission (Table 2). In the multivariate model, only higher levels of anhedonia continued to predict a longer time until remission (Table 2).
Baseline Dimension Scores and Number of Depression-Free Days Through Continuation Treatment
In the univariate models, all depression symptom dimensions were significant predictors of a fewer number of depression-free
Discussion
This study examined how symptom dimensions of depression may predict indices of recovery among SSRI-resistant adolescents enrolled in second-step treatment as part of the TORDIA trial. Anhedonia emerged as a key dimension predicting recovery. Anhedonia predicted a longer time to remission when all five symptom dimensions of depression were included simultaneously in a predictive model. Moreover, anhedonia continued to predict time to remission when examined simultaneous to total CDRS-R score.
References (36)
- et al.
Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS)
J Am Acad Child Adolesc Psychiatry
(2006) - et al.
Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): Acute and long-term outcomes
J Am Acad Child Adolesc Psychiatry
(2009) - et al.
Early prediction of acute antidepressant treatment response and remission in pediatric major depressive disorder
J Am Acad Child Adolesc Psychiatry
(2009) - et al.
Treatment of selective serotonin reuptake inhibitor-resistant depression in adolescents: Predictors and moderators of treatment response
J Am Acad Child Adolesc Psychiatry
(2009) - et al.
Predictors of treatment efficacy in a clinical trial of three psychosocial treatments for adolescent depression
J Am Acad Child Adolesc Psychiatry
(1998) - et al.
Predictors and moderators of acute outcome in the Treatment for Adolescents with Depression Study (TADS)
J Am Acad Child Adolesc Psychiatry
(2006) - et al.
Cognitive-behavioral group treatment of adolescent depression: Prediction of outcome
Behav Ther
(1992) - et al.
Substance use and the Treatment of Resistant Depression in Adolescents
J Am Acad Child Adolesc Psychiatry
(2009) - et al.
The current status of research on the structure of evaluative space
Biol Psychol
(2010) The teen brain: insights from neuroimaging
J Adolesc Health
(2008)
The emergence of depression in adolescence: Development of the prefrontal cortex and the representation of reward
Neurosci Biobehav Rev
Where's the fun in that?Broadening the focus on reward function in depression
Biol Psychiatry
The role of the nucleus accumbens and rostral anterior cingulate cortex in anhedonia: Integration of resting EEG, fMRI, and volumetric techniques
NeuroImage
Daily emotional dynamics in depressed youth: A cell phone ecological momentary assessment study
J Exp Child Psychol
Reconsidering anhedonia in depression: Lessons from translational neuroscience
Neurosci Biobehav Rev
The Treatment for Adolescents with Depression Study (TADS): Long-term effectiveness and safety outcomes
Arch Gen Psychiatry
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial
JAMA
Treatment of Resistant Depression in Adolescents (TORDIA): Week 24 outcomes
Am J Psychiatry
Cited by (309)
Personality characteristics, not clinical symptoms, are associated with anhedonia in a community sample: A preliminary investigation
2023, Journal of Psychiatric Research
Funded by National Institute of Mental Health grants MH61835 (Pittsburgh); MH61856 (Galveston); MH61864 (University of California–Los Angeles); MH61869 (Portland); MH61958 (Dallas); and MH62014 (Brown), T32MH018951 (D.L.M., T.M.O., D.A.B); and the Advanced Center for Early-Onset Mood and Anxiety Disorders (MH66371, D.A.B.).
The statistical experts for this study were Thomas M. Olino, Ph.D., and Giovanna Porta, M.S.
The authors thank the youth, families, staff, and colleagues who made this project possible. The opinions and assertions contained in this report are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of Health and Human Services, the National Institutes of Health, or the National Institute of Mental Health.
Disclosure: Dr. Asarnow has received research support from the National Institute of Mental Health (NIMH). She has received honoraria from the California Institute of Mental Health, Hathaways-Sycamores, Casa Pacifica, and the Melissa Institute. Dr. Brent has received research support from NIMH. He has received royalties from Guilford Press and has served as Editor for UpToDate Psychiatry. Dr. Emslie has received research support from Eli Lilly and Co., Forest, GlaxoSmithKline, and Somerset. He has served as a consultant for Biobehavioral Diagnostics, Eli Lilly and Co., GlaxoSmithKline, INC Research, Lundbeck, Pfizer, Seaside Therapeutics, Shire, Valeant, and Wyeth. He has served on the speakers' bureau for Forest. Dr. Keller has served as a consultant to or received honoraria from Abbott, CENEREX, Cephalon, Cypress Bioscience, Cyberonics, Forest, Janssen, JDS, Medtronic, Organon, Novartis, Pfizer, Solvay, Wyeth, and Sierra Neuropharmaceuticals. He has received research support from Pfizer. He has served on the advisory boards for Abbott, Bristol-Myers Squibb, CENEREX, Cyberonics, Cypress Bioscience, Forest, Janssen, Neuronetics, Novartis, Organon, and Pfizer. Dr. Wagner has received honoraria from the American Psychiatric Association, Physicians Postgraduate Press, CMP Medica, the American Academy of Child and Adolescent Psychiatry, the National Institutes of Health, the Mexican Psychiatric Association, Contemporary Forums, Doctors Hospital in Renaissance, UBM Medica, Quantia Communications, CME LLC, Nevada Psychiatric Association, Slack Inc, Mercy, and Hospital Universitario Ramón y Cajal. Dr. Birmaher has received research support from NIMH. He has served as a consultant for Schering Plough. He has received or will receive royalties from Random House and Lippincott Williams and Wilkins. Dr. Lynch has received research support from NIMH. Drs. McMakin, Olino, Dietz, Ryan, Spirito, Shamseddeen, Clarke, and Kennard, and Ms. Porta, Ms. Mayes, and Mr. Dickerson report no biomedical financial interests or potential conflicts of interest.
This article is discussed in an editorial by Dr. David H. Rubin on page 353.